drugset / Trial / NCT00343759

Presurgical Therapy With Lapatinib to Explore Molecular Determinants of Response to EGFR/erbB2 Targeted Therapy

NCT00343759 ↗

Phase 2 Withdrawn University of Pennsylvania
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to see what kinds of breast tumors will respond to lapatinib. Lapatinib is an experimental medicine which may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start
2006-06
Primary completion
2009-05
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Lapatinib Small molecule — —

Indications